BMY Stock Dives As Generics, Revlimid Rivals Slam 2022 Outlook

Bristol Myers Squibb (BMY) took a machete to its 2022 outlook on Friday amid new generic competitors, and BMY inventory toppled.


For the yr, the corporate lower away $500 million from its outlook for Revlimid and Abraxane, a pair of most cancers therapies which have not too long ago misplaced patent protection. Teva Pharmaceutical (TEVA) launched its Revlimid generic final month.

Income from each oncology meds tumbled within the first quarter, with Abraxane taking a double-digit hit. Worldwide gross sales of Revlimid crashed 23% to $759 million “pushed by generic erosion throughout a number of European Union international locations and Canada,” Bristol Myers stated. Alternate charges additionally impacted gross sales.

In morning buying and selling on in the present day’s inventory market, BMY inventory tumbled 4.2% close to 74.

BMY Inventory: New Merchandise Develop

General, first-quarter metrics topped Wall Avenue’s expectations. Bristol Myers earned $1.96 per share, minus some objects, on $11.65 billion in gross sales. Earnings climbed 13% larger and topped views by a nickel, as gross sales rose 5% and beat expectations for $11.35 billion, in accordance with FactSet.

Regardless of Revlimid and Abraxane troubles — down a respective 5% and 32% — different merchandise posted sturdy features within the first quarter. Bristol Myers’ greatest moneymaker, blood thinner Eliquis, grew 14% to $3.21 billion in gross sales. Opdivo, a most cancers drug, generated $1.92 billion, up 15%.

Bristol Myers additionally reported double-digit will increase for newer merchandise Reblozyl, Onureg and Inrebic. Reblozyl treats anemia in adults with beta thalassemia. The latter two are most cancers therapies. All three are small contributors to the top-line.

However the pharmaceutical big lower its gross sales forecast for 2022. Now, Bristol Myers expects gross sales to be flat vs. its prior view for a low single-digit enhance to $47 billion. Additional, Bristol lowered its per-share earnings outlook to $7.44-$7.74 per share, down 21 cents on the midpoint.

BMY inventory inventory analysts had predicted adjusted revenue of $7.73 a share on $49.95 billion in gross sales.

Observe Allison Gatlin on Twitter at @IBD_AGatlin.


Sanofi Scores A Large Beat As Dupixent Snags The Highlight, Once more

Biotech Behemoth Amgen Tops First-Quarter Views, However 2022 Steering Lags

Wanting For The Subsequent Large Inventory Market Winners? Begin With These 3 Steps

IBD Digital: Unlock IBD’s Premium Inventory Lists, Instruments And Evaluation As we speak

Choices Buying and selling: How To Begin Utilizing Choices, How To Handle Threat

Source link

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button